Catheter Precision (VTAK) stock saw major gains on Monday after the medical device company’s LockeT was registered and approved in the UK. This was the final step needed to begin sales of the suture retention device in the UK after it received a CE Mark for European approval and distribution in May 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Catheter Precision will sell LockeT through UK-based value-added distributor HC21. The company has already worked with this distributor for years, selling other products in the region. This agreement was updated to include sales of LockeT.
Fatih Ayoglu, Catheter Precision Sales Manager EMEA & APAC, said, “We are proud to announce the approval of LockeT for use in the United Kingdom, marking a significant milestone in our mission to support healthcare systems with innovative, patient-centric solutions. With the NHS recently achieving its first reduction in waiting lists in 17 years, LockeT is poised to contribute meaningfully to this momentum by helping clinicians deliver more treatments, more efficiently.”
Catheter Precision Stock Movement Today
Catheter Precision stock was up 72.03% in pre-market trading on Monday, following a 10.74% fall on Friday. The company’s shares have also declined 69.54% year-to-date and 93.78% over the past 12 months. Today’s movement came with heavy trading, as some 23 million shares changed hands, compared to a three-month daily average of about 92,000 units.
Is Catheter Precision Stock a Buy, Sell, or Hold?
Turning to Wall Street, coverage of Catheter Precision stock is thin. Fortunately, TipRanks’ AI analyst Spark has it covered. Spark rates VTAK stock a Neutral (41) with no price target. It cites “significant financial and operational challenges with ongoing losses and negative cash flow” as reasons for this stance.
